| Identification | Back Directory | [Name]
2-[2-[2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHANOL | [CAS]
24342-68-5 | [Synonyms]
BnO-PEG6-OH
Benzyl-PEG7
Benzyl-PEG6
HEXAETHYLENE GLYCOL MONOBENZYL ETHER
1-phenyl-2,5,8,11,14,17-hexaoxanonadecan-19-ol
19-Phenyl-3,6,9,12,15,18-hexaoxanonadecan-1-ol
2-[2-[2-[2-[2-[2-(BENZYLOXY)ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHANOL | [Molecular Formula]
C19H32O7 | [MDL Number]
MFCD06797107 | [MOL File]
24342-68-5.mol | [Molecular Weight]
372.45 |
| Chemical Properties | Back Directory | [Boiling point ]
473.6±40.0 °C(Predicted) | [density ]
1.097±0.06 g/cm3(Predicted) | [refractive index ]
1.4920 to 1.4960 | [solubility ]
Soluble in DMSO, DCM, DMF | [form ]
clear liquid | [pka]
14.36±0.10(Predicted) | [color ]
Colorless to Light yellow | [CAS DataBase Reference]
24342-68-5 |
| Hazard Information | Back Directory | [Description]
Benzyl-PEG7-alcohol is a PEG chain containing a benzyl protecing group and a primary alcohol group. The benzyl is an alcohol protecting group and can be removed via hydrogenolysis. The alcohol group can react to further derivatize the compound. The hydrophilic PEG chains increase the water solubility of the compound in aqueous media. Longer PEG chains have better water solubility properties relative to shorter PEG chains. | [Uses]
BnO-PEG6-OH is a non-cleavable 6 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). BnO-PEG6-OH is also a PEG-based PROTAC linker can be used in the synthesis of PROTACs[1][2]. | [Biological Activity]
BnO-PEG6-OH is a non-cleavable ADC linker containing 6-unit PEG, which can be used to synthesize antibody drug conjugates (ADC). It is also a PROTAC linker, belonging to the PEG class, which can be used to synthesize PROTAC molecules. | [target]
| Non-cleavable < span> | PEGs | | [IC 50]
Non-cleavable Linker; PEGs | [References]
[1] Shaoyun Xiang, et al. Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses there. Patent WO2016197946A1.
[2] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562. DOI:10.1016/j.ebiom.2018.09.005 |
|
|